Top Midday Gainers

MT Newswires Live

Sep 17, 2024

NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.

More than 50.1 million shares traded intraday compared with a daily average of about 138,000.

Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed "favorable tolerability."

Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.

Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.

Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.

Price: 6.71, Change: +4.17, Percent Change: +164.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2468332826"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468332826\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2468332826?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-17 02:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468332826","market":"nz","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.</p><p>More than 50.1 million shares traded intraday compared with a daily average of about 138,000.</p><p>Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed \"favorable tolerability.\"</p><p>Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.</p><p>Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.</p><p>Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.</p><p>Price: 6.71, Change: +4.17, Percent Change: +164.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-17 02:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.</p><p>More than 50.1 million shares traded intraday compared with a daily average of about 138,000.</p><p>Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed \"favorable tolerability.\"</p><p>Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.</p><p>Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.</p><p>Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.</p><p>Price: 6.71, Change: +4.17, Percent Change: +164.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVL","symbol_name":"Nuvalent, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468332826","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468332826","pubTimestamp":1726509822,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NuCana  shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.More than 50.1 million shares traded intraday compared with a daily average of about 138,000.Nuvalent  said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed \"favorable tolerability.\"Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.Zentalis Pharmaceuticals  said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.Price: 6.71, Change: +4.17, Percent Change: +164.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVL":"Nuvalent, Inc.","BK4539":"次新股","ZNTL":"Zentalis Pharmaceuticals, LLC","BK4139":"生物科技","NCNA":"Nucana PLC"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZNTL":0.9,"NCNA":1,"NUVL":0.9},"content_text":"NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.More than 50.1 million shares traded intraday compared with a daily average of about 138,000.Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed \"favorable tolerability.\"Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.Price: 6.71, Change: +4.17, Percent Change: +164.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}